Researchers isolated a molecule that may be under-produced in the guts of patients
Researchers at the Weizmann Institute of Science have shown in mice that intestinal microbes, collectively termed the gut microbiome, may affect the course of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. As reported today in Nature,progression of an ALS-like disease was slowed after the mice received certain strains of gut microbes or substances known to be secreted by these microbes. Preliminary results suggest that the findings on the regulatory function of the microbiome may be applicable to human patients with ALS.
“Our long-standing scientific and medical goal is to elucidate the impact of the microbiome on human health and disease, with the brain being a fascinating new frontier,” says Prof. Eran Elinav of the Immunology Department. His team performed the study together with that of Prof. Eran Segal of the Computer Science and Applied Mathematics Department. Segal elaborates: “Given increasing evidence that microbiome affects brain function and disease, we wanted to study its potential role in ALS.” The study was led by postdoctoral fellows Drs. Eran Blacher and Stavros Bashiardes, and by staff scientist Dr. Hagit Shapiro, all in the Elinav lab. They collaborated with Dr. Daphna Rothschild, a postdoctoral fellow in Eran Segal’s lab, and Dr. Marc Gotkine, Head of the Motor Neuron Disease Clinic at Hadassah Medical Center, as well as with other scientists from Weizmann and elsewhere.
The scientists started out demonstrating in a series of experiments that the symptoms of an ALS-like disease in transgenic mice worsened after these mice were given broad-spectrum antibiotics to wipe out a substantial portion of their microbiome. In addition, the scientists found that growing these ALS-prone mice in germ-free conditions (in which, by definition, mice carry no microbiome of their own), is exceedingly difficult, as these mice had a hard time surviving in the sterile environment. Together, these results hinted at a potential link between alterations in the microbiome and accelerated disease progression in mice that were genetically susceptible to ALS.
Next, using advanced computational methods, the scientists characterized the composition and function of the microbiome in the ALS-prone mice, comparing them to regular mice. They identified 11 microbial strains that became altered in ALS-prone mice as the disease progressed or even before the mice developed overt ALS symptoms. When the scientists isolated these microbial strains and gave them one by one – in the form of probiotic-like supplements – to ALS-prone mice following antibiotic treatment, some of these strains had a clear negative impact on the ALS-like disease. But one strain, Akkermansia muciniphila, significantly slowed disease progression in the mice and prolonged their survival.
To reveal the mechanism by which Akkermansia may be producing its effect, the scientists examined thousands of small molecules secreted by the gut microbes. They zeroed in on one molecule called nicotinamide (NAM): Its levels in the blood and in the cerebrospinal fluid of ALS-prone mice were reduced following antibiotic treatment and increased after these mice were supplemented with Akkermansia, which was able to secrete this molecule. To confirm that NAM was indeed a microbiome-secreted molecule that could hinder the course of ALS, the scientists continuously infused the ALS-prone mice with NAM. The clinical condition of these mice improved significantly. A detailed study of gene expression in their brains suggested that NAM improved the functioning of their motor neurons.
One strain significantly slowed disease progression in the mice and prolonged their survival
Finally, the researchers examined the microbiome and metabolite profiles of 37 human ALS patients and compared them to those of family members sharing the same household. A detailed genomic analysis suggested that the gut microbiomes of ALS patients were distinct in composition and functional features from those of healthy controls. In particular, numerous microbial genes involved in the synthesis of NAM were significantly suppressed in ALS patients. An analysis of thousands of small molecules in the blood also revealed a distinct pattern in ALS patients as compared to controls. Here too, many of the intermediary molecules involved in the NAM synthesis were altered in the blood of ALS patients. When the researchers tested the levels of NAM itself, they found these to be significantly reduced in both the blood and the brain of 60 human ALS patients as compared to controls. Moreover, there was a correlation between reduced NAM levels and the degree of muscle weakness in the patients.
“These findings are only a first step towards achieving a comprehensive understanding of the potential impact of the microbiome on ALS,” Elinav says, “but they suggest that in the future, various means of altering the microbiome may be harnessed for developing new therapeutic options for ALS.”
Learn more: Gut Microbes May Affect the Course of ALS
The Latest on: Amyotrophic lateral sclerosis
via Google News
The Latest on: Amyotrophic lateral sclerosis
- BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALSon July 2, 2020 at 3:57 am
With this press release, BrainStorm has now fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently ...
- Amylyx Pharmaceuticals Raises $30 Million in Series B Fundingon July 1, 2020 at 5:00 am
Amylyx Pharmaceuticals today announced it has closed an oversubscribed $30 million Series B financing, led by Morningside Ventures.
- QurAlis Announces Agreement to Strengthen ALS Pipelineon July 1, 2020 at 4:00 am
QurAlis Corporation, a biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, ...
- 2 months after launch, QurAlis nabs early ALS compounds from Eli Lillyon July 1, 2020 at 3:55 am
In May, startup QurAlis got a $42 million series A toward targeting the genetic causes of two rare diseases: amyotrophic lateral sclerosis and genetically related frontotemporal dementia.
- GeNeuro enrolls first patient in temelimab Phase 2 multiple sclerosis trial in collaboration with the Karolinska Institutet’s Academic Specialist Center (ASC)on June 24, 2020 at 10:30 pm
Regulatory News: GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving th ...
- Early psychological support helpful for ALS patientson June 19, 2020 at 5:00 pm
For patients suffering from Amyotrophic Lateral Sclerosis (ALS), and their families, a neurology specialist recommends early psychological support because the disease is likely to cause despair ...
- NIH announces new Transformative Research Award program for ALSon June 17, 2020 at 8:13 am
The National Institutes of Health plans to invest $25 million over five years in a new program to spur innovative research on amyotrophic lateral sclerosis (ALS), a progressive and fatal neurological ...
- Link between ALS and Alzheimer's disease can help advance the search for new therapieson June 15, 2020 at 11:38 pm
On the surface, amyotrophic lateral sclerosis (ALS) and Alzheimer's disease share two commonalities: Both are progressively debilitating neurodegenerative conditions--meaning symptoms get worse ...
- Cortical Hyperexcitability May Precede The Onset Of Familial Amyotrophic Lateral Sclerosison June 13, 2020 at 5:00 pm
The patients were clinically graded using the amyotrophic lateral sclerosis functional rating scale revised (ALSFRS-R), with a maximum score of 48 when there is no disability. Muscle strength was ...
- UMSOM researchers identify how certain gene mutations cause ALSon June 10, 2020 at 4:58 pm
Researchers at the University of Maryland School of Medicine (UMSOM) have identified how certain gene mutations cause amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
via Bing News